Compare IMNM & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | AXGN |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2020 | 2013 |
| Metric | IMNM | AXGN |
|---|---|---|
| Price | $18.07 | $43.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $32.80 | ★ $42.33 |
| AVG Volume (30 Days) | ★ 1.2M | 864.5K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,941,000.00 | ★ $225,208,000.00 |
| Revenue This Year | N/A | $20.57 |
| Revenue Next Year | $1,127.34 | $16.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.21 |
| 52 Week Low | $7.96 | $9.22 |
| 52 Week High | $27.65 | $45.83 |
| Indicator | IMNM | AXGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 60.55 |
| Support Level | $16.81 | $29.48 |
| Resistance Level | $19.16 | $44.83 |
| Average True Range (ATR) | 0.92 | 2.11 |
| MACD | -0.21 | 0.15 |
| Stochastic Oscillator | 1.24 | 85.42 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.